We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

272 hedge funds and large institutions have $6.44B invested in Amicus Therapeutics in 2020 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 88 increasing their positions, 99 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 29

64% more capital invested

Capital invested by funds: $3.92B → $6.44B (+$2.52B)

8% more funds holding

Funds holding: 251272 (+21)

8% more call options, than puts

Call options by funds: $85.2M | Put options by funds: $79.1M

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

0.33% less ownership

Funds ownership: 107.52%107.19% (-0.33%)

11% less repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 99

Holders
272
Holders Change
+21
Holders Change %
+8.37%
% of All Funds
4.81%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
50
Increased
88
Reduced
99
Closed
29
Calls
$85.2M
Puts
$79.1M
Net Calls
+$6.15M
Net Calls Change
-$17.5M
Name Holding Trade Value Shares
Change
Change in
Stake
PA
1
Perceptive Advisors
New York
$580M -$205K -10,000 -0%
Vanguard Group
2
Vanguard Group
Pennsylvania
$551M +$13.5M +657,866 +3%
BlackRock
3
BlackRock
New York
$505M +$18.6M +908,634 +4%
RG
4
Redmile Group
California
$476M -$50.2M -2,455,317 -11%
Morgan Stanley
5
Morgan Stanley
New York
$294M +$33.1M +1,617,072 +15%
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$260M -$58.5M -2,859,051 -20%
Wellington Management Group
7
Wellington Management Group
Massachusetts
$234M +$84.5M +4,133,312 +69%
ACA
8
Avoro Capital Advisors
New York
$208M -$37.8M -1,850,000 -17%
JP Morgan Chase
9
JP Morgan Chase
New York
$195M +$3.23M +158,151 +2%
State Street
10
State Street
Massachusetts
$183M -$20.9M -1,019,668 -11%
PAI
11
Palo Alto Investors
California
$182M
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$163M -$5.41M -264,668 -4%
LPC
13
Lone Pine Capital
Connecticut
$154M +$137M +6,678,788 New
Deutsche Bank
14
Deutsche Bank
Germany
$127M -$10.1M -491,838 -8%
Jennison Associates
15
Jennison Associates
New York
$109M -$13.4M -657,222 -12%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$93.7M +$4.48M +219,012 +6%
Fidelity Investments
17
Fidelity Investments
Massachusetts
$85.5M -$14.1M -689,233 -16%
Macquarie Group
18
Macquarie Group
Australia
$75.9M +$52M +2,543,281 +342%
Northern Trust
19
Northern Trust
Illinois
$74.5M -$1.61M -78,592 -2%
Victory Capital Management
20
Victory Capital Management
Texas
$73.7M -$13M -635,449 -17%
Goldman Sachs
21
Goldman Sachs
New York
$68.2M +$8.49M +415,368 +16%
ClearBridge Investments
22
ClearBridge Investments
New York
$67.4M -$27M -1,320,992 -31%
Norges Bank
23
Norges Bank
Norway
$63.4M -$19.7M -963,604 -26%
N
24
Nuveen
North Carolina
$61.4M -$736K -36,009 -1%
AG
25
Artal Group
Luxembourg
$57.7M -$10.2M -500,000 -17%

FOLD Hedge Fund Activity: Q4 2020 in Review

272 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2020, worth a combined $6.44B — up 64% from $3.92B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new FOLD positions and 29 closed out — a net gain of 21 holders — while 88 added to existing stakes and 99 trimmed.

The largest buyer was Lone Pine Capital, opening a new position worth an estimated $137M. The largest seller was Janus Henderson Group, cutting an estimated $58.5M.

  • 272 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2020, up from 251 in Q3 2020.
  • Funds reported $6.44B of Amicus Therapeutics stock for Q4 2020, up 64% quarter-over-quarter.
  • 50 funds opened new Amicus Therapeutics positions in Q4 2020 and 29 closed out, a net change of +21 holders.
  • The largest Amicus Therapeutics buyer in Q4 2020 was Lone Pine Capital, an estimated $137M added.
  • The largest Amicus Therapeutics seller in Q4 2020 was Janus Henderson Group, an estimated $58.5M sold.

Based on aggregated 13F filings for Q4 2020.